Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President Donald Trump’s sweeping tariffs. The S&P 500 cratered Thursday following news ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 12.66%, which has investors questioning if this is right time to ...

Organizations that develop sophisticated approaches to IP risk management can protect their exit potential and create ...

Healthcare and medical manufacturing in Australia is gaining momentum with ASX companies at the forefront of growth.

US indices retreat on tariff worries as VIX jumps to 22.44. Nvidia drops 3.9%, Microsoft falls 2.2%, while defensive sectors ...

Learn more about whether Halozyme Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

President Donald Trump's imposition of a 20 percent blanket tariff on imports has sent shockwaves through the global economy, ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...